260 related articles for article (PubMed ID: 33434947)
21. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
23. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
24. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
25. Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.
Sala-Rabanal M; Li DC; Dake GR; Kurata HT; Inyushin M; Skatchkov SN; Nichols CG
Mol Pharm; 2013 Apr; 10(4):1450-8. PubMed ID: 23458604
[TBL] [Abstract][Full Text] [Related]
26. Stereoselectivity in Cell Uptake by SLC22 Organic Cation Transporters 1, 2, and 3.
Gebauer L; Jensen O; Rafehi M; Brockmöller J
J Med Chem; 2023 Dec; 66(23):15990-16001. PubMed ID: 38052451
[TBL] [Abstract][Full Text] [Related]
27. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
28. Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families.
Chen J; Brockmöller J; Seitz T; König J; Chen X; Tzvetkov MV
Biol Chem; 2017 Feb; 398(2):237-249. PubMed ID: 27676604
[TBL] [Abstract][Full Text] [Related]
29. A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
Luo L; Ramanathan R; Horlbogen L; Mathialagan S; Costales C; Vourvahis M; Holliman CL; Rodrigues AD
Anal Chem; 2020 Jul; 92(14):9745-9754. PubMed ID: 32551505
[TBL] [Abstract][Full Text] [Related]
30. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
[TBL] [Abstract][Full Text] [Related]
31. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
32. Association of
Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation in organic cation transporters and considerations in drug development.
Varma MVS
Expert Opin Drug Metab Toxicol; 2023 Mar; 19(3):149-164. PubMed ID: 37070463
[TBL] [Abstract][Full Text] [Related]
34. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
[TBL] [Abstract][Full Text] [Related]
35. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
[TBL] [Abstract][Full Text] [Related]
36. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
37. Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.
Reznicek J; Ceckova M; Cerveny L; Müller F; Staud F
Xenobiotica; 2017 Jan; 47(1):77-85. PubMed ID: 27052107
[TBL] [Abstract][Full Text] [Related]
38. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
Guo D; Yang H; Li Q; Bae HJ; Obianom O; Zeng S; Su T; Polli JE; Shu Y
Pharm Res; 2018 Sep; 35(11):204. PubMed ID: 30191328
[TBL] [Abstract][Full Text] [Related]
39. Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).
Saad AAA; Zhang F; Mohammed EAH; Wu X
Biol Pharm Bull; 2022; 45(4):382-393. PubMed ID: 35370262
[TBL] [Abstract][Full Text] [Related]
40. Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters.
Jensen O; Rafehi M; Tzvetkov MV; Brockmöller J
Biochem Pharmacol; 2020 Jan; 171():113731. PubMed ID: 31783011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
